Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

Recruiting

Phase 2

Medication with Radiation TherapyReversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06912763

Conditions

Fibrosis Syndrome

Lymphedema

Head &Amp; Neck Cancer

Fibrosis

Eligibility Criteria

Sex: Female

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Pravastatin (drug)

Pentoxifylline

ketoprofen

Pirfenidoneone

Standard of Care (SOC)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-10-31. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-10-10.